Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLN-2501
- Development stage
- Preclinical
- Lead developer
- PeriFlow Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
CLN-2501 is a first-in-class, selective smooth muscle myosin inhibitor being developed as a capillary-selective vasodilator to treat capillary no-reflow (CNR) following acute myocardial infarction (AMI). Developed by Motorpharma (a spinout of Eötvös Loránd University) and licensed to PeriFlow Therapeutics, CLN-2501 directly binds to smooth muscle myosin (specifically Myosin-11) in capillary pericytes, relaxing the pathological hypercontraction that restricts microvascular blood flow after reperfusion. In preclinical models of cardiac and renal ischemia, CLN-2501 rapidly reopened capillaries, restored blood flow, reduced infarct size, and improved survival without affecting systemic blood pressure. The drug is also being explored for other ischemic conditions, including acute kidney injury, ischemic stroke, and organ transplantation, and is advancing toward clinical development in the United States.
- Other names
- Compound 2501Compound2501Compound-2501R(+)-2501R(+)2501
02
Targets
MYH11 (Myosin heavy chain 11)
Beyond the preview
Go deeper on CLN-2501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLN-2501.